Galapagos Reports the First Patient Dosing of GLPG3667 in the P-II Study (GALARISSO) for the Treatment of Dermatomyositis

Shots:

The first patient has been dosed in the P-II trial (GALARISSO) evaluating the efficacy, safety, tolerability, PK & PD of GLPG3667 (150mg, qd) vs PBO in ~62 adult patients with DM for 24wks.
The 1EPs of the study is the proportion of patients with minimal improvement in the signs and symptoms of DM @24wk.
GLPG3667 is a novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor & is currently in development for the treatment of inflammatory and auto-immune diseases. If GLPG3667 is approved, it has the potential to be the first selective oral TYK2 inhibitor for dermatomyositis

Ref: Globe Newswire | Image: Galapagos

Related News:- Galapagos Reports Results of GLPG3667 in P-Ib Study for the Treatment of Psoriasis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com